Aytu BioPharma Inc (AYTU)
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics in the United States and select international markets. The company’s prescription portfolio includes products for attention deficit hyperactivity disorder, such as Adzenys XR-ODT, Cotempla XR-ODT, and Metadate CD. It also markets pediatric products including Karbinal ER, an extended-release carbinoxamine suspension for allergic conditions, along with Poly-Vi-Flor and Tri-Vi-Flor, fluoride-based multivitamin products for infants and children. Headquartered in Denver, Colorado, the company was previously known as Aytu BioScience, Inc. and adopted its current name in March 2021. The listed security is common stock on NASDAQ under the symbol AYTU.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AYTU
|
$1.87
|
3.5% Upside
|
Fair
|
$9.67
|
434.1% Upside
|
Bargain
|
Good
|
0.0%
|
November 16, 2026
|
0.6x
|
0.3x
|
19.669 M
|
11.467 M
|
46.5%
|
70.8%
|
-6.9
|
-22.8%
|
